Why Unicycive Therapeutics, Inc.’s (UNCY) Stock Is Down 5.33%
As of Monday, August 24, Unicycive Therapeutics, Inc.’s UNCY share price has dipped by 5.33%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Stock Evaluator: Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. UNCY
$5.16
-0.14
-2.64%
September 4, 2026 4:00:00 PM
EST
Volume: 492,854
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Commentary & Analysis
Why Unicycive Therapeutics, Inc.’s (UNCY) Stock Is Up 5.62%
As of Wednesday, August 12, Unicycive Therapeutics, Inc.’s UNCY share price has surged by 5.62%, which has investors questioning if this is right time to sell.Michael Rose
Why Unicycive Therapeutics, Inc.’s (UNCY) Stock Is Down 6.04%
As of Friday, July 31, Unicycive Therapeutics, Inc.’s UNCY share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Unicycive Therapeutics, Inc.’s (UNCY) Stock Is Up 5.10%
As of Wednesday, July 08, Unicycive Therapeutics, Inc.’s UNCY share price has surged by 5.10%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Unicycive Therapeutics, Inc.’s (UNCY) Stock Is Down 5.06%
As of Monday, July 06, Unicycive Therapeutics, Inc.’s UNCY share price has dipped by 5.06%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | UNCY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $143.7 | $282.4 | 24% |
|
| Shares Out (Mil) | 26.9 | 54.0 | 35% |
|
| Institutional Ownership | 94.7% | 93.1% | 65% |
|
| Float (Mil) | 27.2 | 42.2 | 34% |
|
| Beta | 1.78 | 0.94 | 88% |
|
| Avg Daily Volume (000s) | 636 | 482 | 64% |
|
| Price Change (52-week) |
19.4% | 59.9% | 63% |
|
| Growth | UNCY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (63.2%) | (10.1%) | 5% |
|
| EPS (5yr) | 8.9% | 15.9% | 45 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 63.0% | (15.6%) | 96% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 7 | 7 | |
| Current EPS | ($0.314) | ($1.209) | $1.413 | |
| Month Ago EPS | ($0.340) | ($1.415) | $5.146 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | $0.164 | ($0.978) | $6.039 | |
| Year/Year Chg | 390.6% | (27.7%) | (539.6%) | |
| Financials | UNCY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($35) | ($43) | 19% |
|
| EPS (TTM) | ($1.559) | ($1.500) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($28) | ($31) | 13% |
|
| Net Cash Flow (TTM) (Mil) | $22 | $2 | 63% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $89 | $190 | 20% |
|
| Valuation | UNCY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.70 | 2.84 | 61% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | UNCY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (69.0%) | (47.7%) | 9% |
|
| ROE | (101.1%) | (55.0%) | 9% |
|
| Liabilities to Assets | 26.0% | 29.8% | 18% |
|
| F-Score | 3 | 3 | 18% |
|
Unicycive Therapeutics, Inc. did not pass any screens on 9/4/2026.
